F. Hoffmann-La Roche AG wades into calcium release-activated calcium (CRAC) channels
Disclosed are compounds of Formula (I), useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.
Sci: I've this a hundred times, there will be numerous players in the game, ZLCS is a front runner with first in class candidates and the patents to back them up. The more activity by others the better it gets for ZLCS. An excited industry means an excited Wall Street and we all know what happens when Wall Street gets excited. Justified or not it drives the price of every player up and the real players up even more.
The down side is as more interest is generated the more likely a suitor will come calling, and if ZLCS were to get bought out we all end up takeing it in the shorts. Justin's comment to Gar (I think it was Gar) that $5.00 would be a no brainer didn't bode well with me. I didn't get in this for chump change.
Jim Long and calm
I also believe that calcium channel interest by other pharmaceutical companies and academia, across the board, is VERY positive for Zalicus. If Renz said a 5 PPS buyout offer would be a "no brainer", it makes no sense. Unless Justin Renz does not believe that Z160 can reach the pharmacy shelves, then its worth 0 PPS.
Listening to Dr. Corrigan, he tells us that Zalicus is a binary stock worth either 0 PPS or 100 PPS, but not 5 PPS. 0 or 100 PPS is what his opening statement in his last presentation tells us. Here it is...
"Today I hope to really excite you about a time in our company that we've been waiting for for a very long time. I'm Mark Corrigan, I'm a physician by training. I came up through large pharmaceutical company in Pharmacia, subsequently ran research and development for Sepracor for seven years prior to taking the helm at Zalicus and have been working there for the last three and a half years. Our mission is nothing short of inventing new treatments for pain. That is, novel approaches, and today I am going to be telling you about it. Pain is ubiquitous. All of us have experience it. It is part and parcel of every disease and illness that physicians see, and despite that there has not been a novel pain technology produced in thirty years. We at Zalicus hope to change that."
"Unmet need remains in neuropathic and nociceptive pain markets due to side effects and abuse liability of existing therapies. Combined sales of ~$16 billion in the U.S. and ~$30 billion worldwide in 2010."
If Z160 is +30% effective, it will reach the shelves and capture $1.5 billion annually, making our buyout price conservatively closer 40 to 80 PPS.
"When Abbott announced its full-year results last week, its anti-TNF inhibitor product Humira delivered a stronger-than-expected 23.1 percent year-on-year increase in Q4 sales (recorded at $2.7 billion). Annual sales for 2012 stood at $9.3 billion, cementing the status of Humira as one of the biggest selling products..."